iTrack Advance: advancing canaloplasty to the next level

The ground-breaking iTrack™ Advance takes the established effectiveness(1), accuracy and reliability of the original iTrack™ canaloplasty microcatheter and combines it with an ergonomic, easy-to-use handheld injector.
The iTrack™ Advance has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma.
iTrack™ Advance has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.
For more information, including important safety information, please visit iTrack-Advance.com
(1) Gallardo MJ. 36-month effectiveness of ab-interno canaloplasty standalone versus combined with cataract surgery for the treatment of open-angle glaucoma. Ophthalmol Glaucoma. 2022 Feb 17:S2589-4196(22)00025 - 4. doi: 10.1016/j.ogla.2022.02.007. Epub ahead of print. PMID: 35183815.

[@satnam300]

Look And Feel is Very Beautiful. Animation Looks Very polish...:)

[@boldizsarszabo]

kurwa